Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Among authors: llanos jp. Ann Allergy Asthma Immunol. 2024 Sep;133(3):310-317.e4. doi: 10.1016/j.anai.2024.04.031. Epub 2024 Apr 30. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article. Clinical Trial.
Burden of disease associated with a COPD eosinophilic phenotype.
Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B. Ortega H, et al. Among authors: llanos jp. Int J Chron Obstruct Pulmon Dis. 2018 Aug 13;13:2425-2433. doi: 10.2147/COPD.S170995. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30147308 Free PMC article.
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma.
Corren J, Wechsler ME, Chupp G, Roseti SL, Hellqvist Å, Martin N, Llanos JP, Ambrose CS, Colice G. Corren J, et al. Among authors: llanos jp. J Allergy Clin Immunol Pract. 2023 Mar;11(3):943-945.e2. doi: 10.1016/j.jaip.2022.10.042. Epub 2022 Nov 11. J Allergy Clin Immunol Pract. 2023. PMID: 36375743 No abstract available.
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, Ambrose CS, Cook B, Martin N, Spahn J, Llanos JP. Corren J, et al. Among authors: llanos jp. Eur Respir J. 2023 Mar 30;61(3):2202202. doi: 10.1183/13993003.02202-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36997233 Free article. No abstract available.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Among authors: llanos jp. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti SL, Ambrose CS, Llanos JP, Cook B, Corren J, Colice G. Menzies-Gow A, et al. Among authors: llanos jp. Ann Allergy Asthma Immunol. 2023 Sep;131(3):343-348.e2. doi: 10.1016/j.anai.2023.05.028. Epub 2023 May 30. Ann Allergy Asthma Immunol. 2023. PMID: 37263380 Free article. Clinical Trial.
Reply to Lipworth and Chan.
Ambrose CS, Israel E, Bowen K, Llanos JP, Martin N, Cook B, Hellqvist Å, Korn S, Menzies-Gow A, Roseti SL, Molfino NA, Griffiths JM, Parnes JR. Ambrose CS, et al. Among authors: llanos jp. Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE. Am J Respir Crit Care Med. 2023. PMID: 37279366 Free PMC article. No abstract available.
33 results